Gardiquimod Explained

Gardiquimod is an experimental drug which acts selectively at both mouse and human forms of toll-like receptor 7 (TLR7). It functions as an immune response modifier.[1] [2] The core structure is 1H-imidazo[4,5-c]quinoline, as found in related drugs such as imiquimod and resiquimod. It is structurally very similar to resiquimod differing only by an oxygen for nitrogen switch.

Notes and References

  1. Ma F, Zhang J, Zhang J, Zhang C . The TLR7 agonists imiquimod and gardiquimod improve DC-based immunotherapy for melanoma in mice . Cellular & Molecular Immunology . 7 . 5 . 381–8 . September 2010 . 20543857 . 4002679 . 10.1038/cmi.2010.30 .
  2. Buitendijk M, Eszterhas SK, Howell AL . Gardiquimod: a Toll-like receptor-7 agonist that inhibits HIV type 1 infection of human macrophages and activated T cells . AIDS Research and Human Retroviruses . 29 . 6 . 907–18 . June 2013 . 23316755 . 3653394 . 10.1089/aid.2012.0313 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Gardiquimod".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.